Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methyl 4-{[({[(2R,5S)-5-{[(2S)-2-(aminomethyl)pyrrolidin-1-yl]carbonyl}pyrrolidin-2-yl]methyl}amino)carbonyl]amino}benzoate is a synthetic small molecule belonging to the class of alpha amino acid amides and amino acid derivatives. It has a molecular formula of C20H29N5O4 and a molecular weight of approximately 403.48 g/mol. The compound is listed in chemical and pharmaceutical databases as an experimental molecule but does not have any approved medical indications or known clinical use as of now. Its mechanism of action, pharmacological activity, and therapeutic potential are not described in public sources; it appears to be primarily referenced for research purposes or as a chemical entity in screening libraries[1][2][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methyl 4-{[({[(2R,5S)-5-{[(2S)-2-(aminomethyl)pyrrolidin-1-yl]carbonyl}pyrrolidin-2-yl]methyl}amino)carbonyl]amino}benzoate.